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Several methods of quantitative risk assessment that have been described recently are
particularly applicable to neurotoxic end points. These methods can be broadly divided into two
types of approaches based on their treatment of dose-response data to estimate risks.
Benchmark approaches estimate risks using variability in response to a fixed dose level in
comparison with background control variability. Probabilistic approaches estimate risks using the
variability in the dose to produce a small effect in the sample population. The current report seeks
to extend the development of probabilistic approaches for neurotoxic end points. Because
behavioral data are often used to assess therapeutic efficacy as well as toxicity (unwanted effects),
this analysis focused on the relative risks of producing these effects with the same agent. The
therapeutic potential of GBR 12909 was determined by its ability to decrease cocaine-maintained
responding in monkeys. The effects of this agent were also assessed in the same monkeys using
food-maintained responding to provide an indication of behavioral toxicity. GBR 12909 decreased
both behaviors, with complete decreases on drug-seeking behavior occurring at doses that had
minimal effects on food-maintained responding. The difference in the estimates of doses to
decrease drug-seeking and food-maintained behavior suggested that specific therapeutic effects
could be obtained in the absence of unwanted side effects for a definable proportion of the
population. These results also suggest that multiple behavioral end points can be useful for
identifying specific effects of chemicals for the purposes of risk assessment. Environ Health
Perspect 104(Suppl 21:391-396 (1996)
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Introduction
Risk assessment is the attempt to estimate agent that produce adverse effects in
the chance ofobtaining an adverse effect of humans, risk assessments are typically based
exposure to an agent. Although it is possible on effects obtained over a range of non-
to predict virtually safe levels ifsufficient toxic-to-toxic doses determined in animals.
information is known about doses of an Such methods were developed initially to
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predict the chance ofproducing carcino-
genic and mutagenic effects with exposure
to ionizing radiation. Higher doses were
often associated with an increased inci-
dence ofcancers, so the focus ofrisk assess-
ment shifted toward the attempt to predict
effects produced by very low doses. Two
problems developed. First, the spontaneous
rate ofcancer production called into doubt
the ability to measure an increase in risks
associated with very low doses ofan agent.
Second, several low-dose extrapolation
approaches were developed based on the
assumption that any increment in dose
would increase the probability ofan effect.
These issues have questioned the relevance
ofthe low-dose extrapolation approach for
other types ofadverse effect. For example,
few neurotoxic events occur spontaneously,
although disease, age, or other processes
may exacerbate their effects. Likewise,
mechanisms such as cellular repair, plastic-
ity, system redundancy, or tolerance may
contribute to the lack ofmeasurable effect
following exposure to low doses of neuro-
toxic agents. Alternatively, some agents have
been simply found to lack effects at low
doses. As a result, risk assessment methodol-
ogy for noncancer end points shifted away
from the estimation ofeffects ofvery low
doses toward the attempt to estimate levels
ofan agent that might be considered safe.
The earliest practice used to predict safe
levels was the acceptable daily intake
approach (ADI), which attempted to
predict a dose (within an order of magni-
tude ofuncertainty) that could be tolerated
over the lifetime without producing harm.
However, while some argue that it was vir-
tually impossible to determine an entirely
safe dose, others pointed to an apparent
inappropriateness ofusing theword "accept-
able" in the context ofa poison. This led to
a revised terminology called the reference
dose (RfD) approach. This approach first
finds a dose level with no effect (i.e., no
observable adverse effect level, or NOAEL)
or a minimal effect (i.e., lowest observable
adverse effect level, or LOAEL) in animals
and then divides this dose by a series of
uncertainty factors (invariably 10-fold each)
to calculate a RfD for humans. The result-
ing RfD could be several orders ofmagni-
tude smaller than the original NOAEL or
LOAEL (1). There have been a number of
criticisms of the RfD approach (2-6),
including a) its dependence on the actual
dose spacing used, b) its failure to incorpo-
rate the slope ofthedose-response function,
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c) a lack of biological justification for
uncertainty factors, d) its questionable
applicability for some types ofdata, e) the
fact that the RfD is not a risk figure but
rather a point estimate ofan exposure at
which risk is considered negligible, and
f) its perverse ability to reward biased risk
assessors with less conservative risk figures
for using small sample sizes. In response, a
new trend in risk assessment that uses more
quantitative approaches has emerged.
These approaches are of interest because
they circumvent many ofthe problems asso-
ciated with the RfD and low-dose extrapola-
tion approaches and thus provide true
quantitative risk estimates. Given the recent
increase in concerns over other end points
such as neurotoxicity (7,8), and the equivo-
cal performance ofthe older approaches to
estimate risks (9,10), the time is ripe to
scrutinize these quantitative methods.
Quantitative approaches generally
describe dose-effect functions in mathe-
matical terms and specifically incorporate
the variability in different parameters ofthis
function to assess risks (6,11). One subfam-
ily ofthese approaches can be characterized
by its focus on variability in an effect at a
fixed-exposure level (effect-tolerance or
benchmark approaches). One advantage of
this approach is that statistical techniques
to fit functions and characterize variability
are readily available. Another subfamily of
approaches is characterized by a focus on
variability in exposure levels that can be
shown to produce a fixed effect (dose-toler-
ance or probabilistic approaches). The
advantage ofthe dose-tolerance approaches
is that they characterize individual differ-
ences, thus providing direct information as
to the potential adequacy ofthe use ofan
uncertainty factor for individual variability
(6). The current report extends the use of
the probabilistic (dose-tolerance) approach
to multiple behavioral end points in the
same organisms to address the specificity of
the effect ofthe agent.
The agent used for these analyses is a
drug that may have therapeutic merit.
Though drugs are not commonly thought
ofas neurotoxicants, any pharmacologist or
toxicologist will acknowledge that high
doses oftherapeutic agents will have adverse
effects. It has been a common practice over
the years to compare doses expected to pro-
duce a therapeutic effect with those
expected to produce a toxic effect. The cur-
rent report departs from this approach by
attempting to compare the riskofproducing
these effects. Another small departure from
standard methods is the use of a different
end point in the current report. Behavioral
toxicology has been primarily concerned
with the direct effects of toxic agents on
learned or acquired behaviors. Most often,
these behaviors are experimentally devel-
oped in the laboratory, typically by train-
ing animals to respond under schedules of
food reinforcement. Stable rates and pat-
terns ofbehavior provide a baseline from
which a dose-effect function can be deter-
mined. While almost all of these studies
have employed behaviors that lead to the
delivery offood as a reinforcer, some others
have shown that the event used to main-
tain behavior can determine different
effects for some agents (12). It has been
known for some time that drugs can be
used to maintain responding (e.g., self-
administration studies). Interestingly, some
toxicants have been shown to serve as rein-
forcers. For example, toluene has been
shown to support responding in monkeys
(13). Little is known of solvent abuse;
however, growing knowledge suggests that,
if left unchecked, drug abuse results in
changes in behavior that are sufficient to
meet the criteria ofa psychiatric disorder
(14). Neurotoxic changes are also seen
with prolonged exposure to drugs ofabuse
(15). Thus, drug abuse may be the most
prevalent form of behavioral toxicology
observable in humans today. One question
is whether a therapeutic agent could be
developed that would decrease drug abuse
but not alterother normal behavior.
Previous studies have shown that oper-
ant responding can be maintained by
cocaine delivery (self-administration), which
provides an animal model ofdrug abuse
(16). Left unrestrained, cocaine self-admin-
istration can occur to the point ofproduc-
ing serious harm in animals (17). Such
excessive behavior may result in neurotoxic
effects in central mesolimbic dopamine
(DA) pathways associated with reinforce-
ment (18). In contrast to some forms of
drug abuse, there is no currently accepted
strategy to treat cocaine abuse. However,
clues from successful treatment approaches
suggest that targeting mechanisms associ-
ated with the abuse potential ofa drug may
lead to a treatment drug. Recently, a
specific neuronal site (the DA reuptake or
transporter) has been identified as a recep-
tor that is strongly associated with the rein-
forcing effects of cocaine (19). Studies
have shown that drugs that bind to this site
need not exhibit reinforcing effects in
humans (20) or in animals (21). These
observations have led to the suggestion that
long-acting DA reuptake inhibitors may
attenuate cocaine-seeking behavior in a
manner similar to the ability ofmethadone
to decrease opiate-seeking behavior or
nicotine patches to decrease smoking (22).
However, there is no clear consensus as to
the type of effect a medication should
exhibit on cocaine self-administration in
animals that would predict its efficacy to
decrease cocaine-seeking behavior in
humans. The current research is meant to
address this issue from a therapeutic point
ofview; however, it is obvious that some
concern should be directed at the potential
toxicity ofsuch an agent. Thus, the current
studies are designed to compare the relative
therapeutic actions ofan agent being devel-
oped to treat cocaine abuse with other
unwanted effects. The current studies focus
on one compound, GBR 12909, which has
previously been shown to exhibit a number
ofeffects similar to those of cocaine and
has a high affinity for the DA reuptake site.
In contrast, because GBR 12909 is long
acting and has a chemical structure unlike
cocaine, it may block the effects ofcocaine.
Interestingly, this drug has been reported
to exhibit a nonstimulant profile ofaction
in normal human volunteers following oral
administration (23). Thus, this agent could
serve as a prototype from which even more
therapeutic and less toxic analogs could be
developed. The primary focus of the cur-
rent work was to separate those effects.
For these purposes, the effects of GBR
12909 on food-maintained behavior were
taken to represent a behaviorally toxic
effect, and its effects on cocaine self-
administration were used as an indication
ofits therapeutic potential.
To accomplish the risk assessment
analysis of these data, methods previously
developed to assess the risks ofexposure to
agents using a single behavioral end point
were used (24). This approach was origi-
nally described by Dews (3,4). Data from
individual subjects are first described by
means ofa mathematical function, and the
dose resulting in a small but measurable
effect is estimated from each function.
Through replications in different subjects,
a distribution ofindividual point estimates
is obtained. The variability in these esti-
mates is used to predict population toler-
ances, from which the proportion of the
population that would be expected to be
affected at lower levels can be determined.
This method has been used extensively to
assess the risks associated with exposure to a
variety oforganic solvents (25-27). These
estimates ofa small decrement in neurobe-
havioral functioning in relatively small
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sample sizes (n= 10-12) agreed well with
established threshold limit values (TLVs). A
subsequent report (28) compared estimates
from small (n= 10) and large (n=40) sample
sizes to illustrate theeffectiveness ofthese rel-
atively small experiments, as well as to com-
pare estimates obtained with this approach
to those ofothers. This approach has also
been compared with other approaches in
terms of its use of the dose-effect data
(6,10), applicability to cross-species extrapo-
lation (29), and ability to characterize the
neurotoxic effects ofthe pesticide carbaryl
(6). The potential advantage ofusing two
end points in the present studies is that the
nonspecific (toxic) effects ofthe agent can
be directly compared to its intended
therapeutic effects, thereby producing a
thzerapeutic ratio.
Methods
This report uses methods that were previ-
ously published (30,31). Briefly, rhesus
monkeys were surgically implanted with a
subcutaneous port/catheter system (32)
and trained to respond under a multiple
fixed-ratio 30-response food presentation
(FRF), fixed-ratio 30-response cocaine
injection (FRC) schedule to establish a
baseline where approximately equal rates of
responding were maintained by food and
cocaine. The acute effects of GBR 12909
were then determined on these perfor-
mances using eight monkeys. Individual
control rates ofresponding for both perfor-
mances were obtained for several noninjec-
tion control sessions and served as a baseline
for each monkey. The effects of pretreat-
ment with GBR 12909 were assessed on
this baseline by comparing the mean over-
all rates of responding during drug ses-
sions with rates during control sessions.
Two advantages ofthese data are that the
effects ofthe agent were well characterized
(doses were assessed 2-3 times per monkey)
and the individual differences in effect
occurring among the monkeys could serve
to model individual differences in the
human population.
GBR 12909 (1-1.7 mg/kg) decreased
responding maintained by cocaine almost
completely without affecting food-main-
tained responding. This type of effect
showed that cocaine-maintained respond-
ing could be decreased by low doses ofthis
drug. With higher doses of GBR 12909,
food-maintained responding decreased.
This effect may have been associated with
a drug-induced disruption of behavior or
because some aspect of food-maintained
responding provided a greater resistance
to the drug effect than that seen with
cocaine-maintained responding. A mean
dose-effect function for each ofthese behav-
ioral end points was then constructed using
the individual data from the eight animals.
While there was no overlap ofthese curves
(i.e., GBR 12909 always decreased cocaine-
maintained responding at lower doses than
food-maintained responding), some animals
were more sensitive to the effects ofGBR
12909 than others. However, traditional
statistical approaches confirmed that GBR
12909 had different effects on these two
behaviors. For example, single factor
repeated measures analysis of variance
(ANOVA) indicated a significant main
effect of maintaining event (F= 18.428;
df= 1,14; p< 0.0007), dose (p<0.)000 1),
and an interaction.
Figure 1 shows the essential elements of
the method of risk assessment applied to
these data. First, the effect ofGBR 12909
on each type of response was determined
relative to each monkey's baseline rate for
each response by dividing rates during drug
sessions by rates during control sessions for
each component. This represents a normal
dose-effect function for a single animal,
only two different end points could be
described. Next, a straight line was fit to the
linear portion (only those doses that pro-
duced greater than a 20% decrement but
less than an 80% decrement in responding)
ofeach curve using linear regression. Effect
100 -
80 -
60 -
40 -
20 -
2 -1 0 1
In dose GBR 12909, mg/kg
Figure 1. Transformed dose-effect summaries of the
rate-decreasing effects of GBR 12909 on responding
maintained under multiple FR30 schedules of cocaine
delivery (solid line) and food-pellet delivery (dotted
line). Effects are the mean ofdouble-determined obser-
vations of the rate-decreasing effects (see text for a
description of the restriction of the range) in eight
monkeys, expressed as a percentage of the individual
baseline rate of responding. Doses were transformed
to the natural logarithm (In). Variability (1 z-score) in
the dose to produce 90 and 10% effects, based on dif-
ferences in the individual curves, is indicated by the
horizontal bars.
(percent ofcontrol) was plotted against the
natural logarithm (ln) of the dose. The
figure shows only the mean circumscribed
descending limb, from 90 to 10% ofcon-
trol. Thevariability (SD) in the 90 and 10%
ofcontrol was determined from the individ-
ual functions (horizontal lines). For exam-
ple, the mean ln dose of GBR 12909 to
produce a 10% decrement in cocaine-main-
tained responding was -1, with a SD of
about 0.5. As is apparent from Figure 1, the
doses of GBR 12909 required to decrease
food-maintained responding were high. In
fact, for three animals complete decreases in
food-maintained responding were not pro-
duced by the highest dose of GBR 12909
studied. Since previous studies suggested
that a higher dose (5.6 mg/kg) would com-
pletely abolish responding, it was conserva-
tively assumed that similar effects would be
obtained in these animals and that it would
be in the best interest ofthe animals to not
test higher doses.
The estimates of risk were then
obtained by calculating the successive prob-
abilities (i.e., p=0.1,p=0.01, p=0.001) of
obtaining a 10% decrement in this group of
animals using a z-score approach. In the
past, only estimates from the low end of
these distributions have been assessed
because ofthe specific interest in the effects
oflow doses. In this study, the overlap of
the effects ofsimilar doses of GBR 12909
on both cocaine- and food-maintained
responding could be directly compared.
Transformation then allowed determina-
tion ofdoses (in milligram per kilogram)
expected to decrease responding by 10% in
the specified proportion (i.e., 1 out of 10,
1 out of 100, etc.) ofthe population (24).
Figure 1 characterizes the descending limbs
ofthe dose-effect curve for each end point.
(A mean curve was never used for the
analysis; it simply represents the mean slope
joining the mean 90 and 10% point esti-
mates.) The mean parameters (a=intercept;
b=slope) for the individual curves, the 90%
effect (in In dose and in milligram per kilo-
gram), and the SD ofIn dose for cocaine-
maintained responding were
FRC, mg/kg
a b 90% (In) 90%
Mean 18.103 -74.52 -1.0538
(SD) (0.4226)
0.37
The resulting risk figures for estimation of
a 90% effect in successively smaller propor-
tions (1/10 [p=0.1], 1/100 [p=0.0I], and
1/1000 [p=0.001]) ofthe population based
on cocaine-maintained respondingwere
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In dose
Dose, mg/kg
The mean par
Probabllity In addition, the effects ofGBR 12909 on 0.1 0.01 0.001 cocaine-maintained responding may also
-0.652 -2.321 -3.076 be similar to those ofdelivering free food
0.19 0.10 0.05 on behavior maintained by food delivery.
ameters for food-maintained However, in contrast to the decrease in
responding were
FRF
cocaine-maintained behavior produced by
GBR 12909, the decrease in food-main-
a b 90%(in) 90%,mg/kg tained behavior by this drug was consid-
170.45 -134.6 0.5579 2.02 ered adverse (i.e., an effect that might
(0.6258) interfere with the normal behavioral func-
tioning). The variability in the likelihood
ofproducing each effect in individual ani-
tulting risk figures for estimation of mals was then used to specify the probabil-
effect in successivelysmaller propor- ityofseeing that effects at doses thatwould
/10 [p=0.1], 1/100 [p=0.01], and be expected to affect certain proportions of
D [p= 0.001 O]) of the population the population.
in food-maintained respondingwere Further analysis ofthe current data was
Probability used to explore potential therapeutic
0.1 0.01 0.001 indices for GBR 12909. Traditional thera-
peutic ratios have been constructed using
glkg 0.72 0.27 0.09 comparable levels ofeffect on different end points (e.g., LD50/ED50). The current
approach could extend these methods to
mparisons of the distributions of compare the extent to which similar levels
o decrease each type ofresponding ofeffect on both behaviors overlapped. For
y t-tests indicated (p<0.001) the example, the low end ofthe distribution of
ral specificity ofthe effects ofGBR effects for food-maintained responding
(i.e., the two behaviors were affected suggests that 1 out of 10 individuals would
rent doses). exhibit a 10% decrease in respondingwhen
lusions
given 0.72 mg/kg GBR 12909. Likewise, 1
out of 100 individuals would be expected
irrent report is not intended to to exhibit this effect when given 0.27
tively explore the relationships mg/kg. For cocaine-maintained responding,
a different effects ofan agent on dif- the high end ofthe distribution suggests
,nd points but rather to extend the that 9 out of 10 individuals would exhibit
ment ofa risk assessment technique at least a 10% decrease in drug-seeking
well-defined data set. The current behavior at 0.45 mg/kg. Thus, a dose could
Is are ofinterest because theydirecdy be conceived that diminished drug-seeking
e sources ofvariability that have been in at least 90% ofthe population and with-
d in other risk assessment processes. out producing adverse effects in 90 to 99%
Lmple, the use ofthe sample variance ofthe population.
nate risks provides data directly rele- In contrast, it may be of interest to
one source ofuncertainty in risk compare the overlap ofahighlytherapeutic
lent (individual differences). In the dose (i.e., the ED90 for cocaine-maintained
iproach this uncertainty factor is typi- responding) with a minimally toxic dose
sumed to be an order ofmagnitude. (i.e., EDIO for food-maintained respond-
irrent studies also suggested that, ing) in order to assess the probabilities of
:here was a clear difference in the obtaining the most benefit at the least cost.
DfGBR 12909 on these two types of Alternatively, it might be argued that only
Dr, the variability in effects on each asingle dose ofGBR 12909 could be given
ed relevant data from which risks at one time, focusing the emphasis ofsuch
oe assessed. analyses on distributions of two different
! current methods established dose- levels ofeffect (e.g., a dose of 1.7 mg/kg
elationships for GBR 12909 on two decreased drug-maintained responding
it behaviors. These dose-effect func- almost completely while having little effect
,uggested that each behavior was on food-maintained responding). Obviously,
i differently by this drug, as expected. the extent to which there is no apparent
2909 decreased drug-seeking behav- overlap between the mean desired and
ese effects may be similar effects to undesired effects suggests the drug may be
ofmethadone to treatheroin or nico- relatively safe, although a 1/10 chance ofan
tches to treat tobacco abuse (28,29). adverse effect may warrant concern. The
present data suggest that there is some
overlap of effects with GBR 12909,
although it is by no means complete. It may
be constructive to compare the degree of
overlap with that ofother therapeutic agents
(e.g., diazepam) when assessed on relevant
behaviors (e.g., punished and nonpunished
responding). In the presentcase, someofthis
overlap may have resulted from the treat-
ment ofthe data. The slope ofthe function
for food-maintained responding was steeper
than that for cocaine-maintained respond-
ing, suggesting that the artificial decreases
imposed for monkeys that did not exhibit
complete decreases in food-maintained
responding mayhave inflatedvariability.
One interesting feature of the current
approach is the variability ofan effect (and
hence, risks estimates) that was almost con-
stant over the range of the dose-effect
function. For example, examination ofthe
variability at different effect levels (i.e., 90,
50, 10%) on each curve demonstrated a
remarkable similarity at different points for
food-maintained responding (from 0.639 at
90% to 0.626 at 10%). Variabilityincreased
slightly with the increasing effect ofGBR
12909 on cocaine-maintained responding
(from 0.423 at 90% to 0.724 at 10%).
These observations illustrate that dose-toler-
ance and benchmark approaches character-
ize variability in a completely different
manner. Confidence intervals invariablyflare
at the high and low ends ofthe dose-effect
function, even ifthe observed variability is
greatest at the intermediate doses. One fea-
ture ofthesehyperbolidike functions is that,
with sufficient variability in the dose-effect
data, this flare may preclude the determina-
tion ofa benchmark dose because the entire
lower confidence interval may never inter-
ceptthe 10% effectlevel.
Afeature ofquantitative approaches that
appears to be gaining acceptance is the use
oflogarithmic conversions ofdose. While
log-normal distributions have been used and
accepted in pharmacology for many years
(33) primarily because receptor interactions
can span orders or magnitude, their use in
risk assessment has received less attention.
Previous studies have pointed to the advan-
tage ofpreventing negative numbers in risk
assessment (3,4) and to the validity oflog-
normal distributions of individual effects
when sufficient numbers ofsubjects are
used (27). Standard benchmark approaches
may also convert doses to log doses in unex-
posed algorithms (2). In the current data
this conversion had an unusual effect on the
upper end ofthe ED estimates. When the
normally distributed ln point estimates were
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converted back to real numbers, the con-
verted distribution dispersed at a logarith-
mic rate ofchange. The result should be
that observed effects rarely exceed those
predicted at either end ofthe distribution,
although in practice predicted effects at the
low end seem to occur with more regular-
ity than at the high end. This could dimin-
ish some concern ofthe predicted overlap
ofthese two effects described above.
Another feature ofthe current method
that deserves consideration is the use of
linear functions to fit individual dose-effect
data. There may be several issues including
the likelihood that other types offunctions
may fit the data better. However, previous
authors have noted that the type of the
function used to fit the linear region usually
has little effect on the risk estimate (24,34).
In fact, traditional statistical techniques
(ANOVA, etc.) may bias the slope ofthe
function by incorporating excessive determi-
nations of0 and 100% effects. Eliminating
excessive determination ofdoses without
effect seems desirable, but it requires an
arbitrary rule for data exclusion. The use of
functions that can effectively use all the data
to more accurately fix the linear portion
(e.g., logistic curves) should be explored.
Linear functions are preferred, of course,
because they strongly suggest that a direct
relationship exists between dose and effect.
While it is obvious that agents may have
many effects, the most parsimonious
conclusion upon observation of a linear
function is that the one that is being mea-
sured is directly affected by the agent.
Unfortunately, not all dose-effect data can
be accurately characterized by a linear func-
tion. For example, there is often an increase
in responding with some agents when
assessed on behavioral measures. These
increases inevitably give way to decreases,
creating an inverted U-shaped function.
Wood and Cox (35) recently reported risk
assessments using data in which low doses
oftoluene increased rates and higher doses
decreased rates. They fit a linear function to
the ascending limb (rate-increasing effects)
alone. While this approach clearly avoids
the issues ofthe interpretation ofa complex
function and uses the most sensitive effect
oftoluene, it questions the issue ofwhether
any effect ofa toxicant is adverse. In the
current studies, effects ofGBR 12909 on
drug-seeking behavior were the most sensi-
tive butwere not considered toxic.
The current report applies a quantita-
tive approach to assess the risks ofobtaining
two different effects with the same agent.
Drug-seeking behavior was targeted for
selective elimination by doses of GBR
12909 that were not expected to produce
toxic effects. It should be clear from these
results that a decrease (or increase) in one
behavior alone may not be the best indica-
tion ofbehavioral toxicity. Likewise, selec-
tive decreases in food-seeking behavior
produced by other agents [e.g., appetite
suppressants (36)] may be an intended
effect. Literature is incomplete on the dif-
ferent behavioral effects that agents can
have on behaviors maintained by different
events. In the absence ofspecific knowledge
ofthe effect ofan agent on behaviors main-
tained by certain events, complete decreases
in responding may warrant concern. When
a single behavior is studied, it must be con-
sidered that doses which decrease respond-
ing completely might decrease all types of
responding completely, a clear reason for
concern. However, when one behavior is
more affected than another, it could be
because the susceptible behavior is less well
maintained. This possibility points to the
importance ofreinforcement processes in
the assessment ofbehavioral toxicology. In
the current case, a decrease in the relatively
well-maintained food-presentation behavior
is clear reason for concern.
The dose-tolerance method was easily
adapted to demonstrate a selective effect of
GBR 12909 on two different behaviors, as
well as to estimate the risks of obtaining
those effects in a population. This method
should be considered positively over other
approaches since it directly employs indi-
vidual differences in sensitivity to an agent
as a metric ofrisk. However, not all types of
end points can be studied using single-sub-
ject, repeated-exposure designs. Recently,
we have developed avariant ofthe dose-tol-
erance approach for use with groups-design
single-exposure data (Bogdan et al., unpub-
lished data). This approach uses an iterating
line-fitting program to calculate all possible
dose-effect combinations that could be cre-
ated from individual effects when different
groups ofanimals are treated with different
doses (e.g., three dose groups with six ani-
mals each would produce a 6x6x6 matrix
yielding 216 possible dose-effect functions).
This approach was very effective when
applied to a data set addressing the effects of
carbaryl on motor activity ofrats (6). The
risk figures it produced were less conserva-
tive than those ofthe current (within-sub-
ject) approach but were more conservative
than those produced by the maximal likeli-
hood estimation/confidence-interval
approach. Future studies will continue to
compare the results ofthese approaches to
provide the practitioner a range ofoptions
for quantitative risk assessment.
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